Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain

被引：0
作者：
D J Müller
C C Zai
M Sicard
E Remington
R P Souza
A K Tiwari
R Hwang
O Likhodi
S Shaikh
N Freeman
T Arenovich
A Heinz
H Y Meltzer
J A Lieberman
J L Kennedy
机构：
[1] Neurogenetics Section,Neuroscience Department
[2] Centre for Addiction and Mental Health,Clinical Research Department
[3] Biostatistical Consulting Service,Department of Psychiatry
[4] Centre for Addiction and Mental Health,Department of Psychiatry
[5] Charité University Medicine Berlin,undefined
[6] Campus Mitte,undefined
[7] Psychiatric Hospital,undefined
[8] Vanderbilt University,undefined
[9] College of Physicians and Surgeons,undefined
[10] Columbia University and The New York State Psychiatric Institute,undefined
来源：
The Pharmacogenomics Journal | 2012年 / 12卷
关键词：
antipsychotic-induced weight gain; schizophrenia; pharmacogenetics; dopamine receptor genes; polymorphisms; haplotypes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Antipsychotic-induced weight gain has emerged as a serious complication in the treatment of patients with most antipsychotics. We have conducted the first in-depth examination of dopamine receptor genes in antipsychotic-induced weight gain. A total of 206 patients (139 of European descent and 56 African Americans) who underwent treatment for chronic schizophrenia or schizoaffective disorder were evaluated after on average over 6 weeks of treatment. Thirty-six tag single nucleotide polymorphisms (SNPs) and one variable-number tandem repeat, spanning the five dopamine receptor genes (DRD1–DRD5) were analyzed. In the total sample, we found a nominally significant association between the DRD2 rs1079598 marker and weight change using a cutoff of 7% gain (P=0.03). When stratifying the sample according to ethnicity and antipsychotics with highest risk for weight gain, we found significant associations in three DRD2 SNPs: rs6277 (C957T), rs1079598 and rs1800497 (TaqIA). The other genes were primarily negative. We provide evidence that dopamine receptor DRD2 gene variants might be associated with antipsychotic-induced weight gain in chronic schizophrenia patients.
引用
收藏
页码：156 / 164
页数：8
相关论文
共 314 条
  • [1] Müller DJ(2006)Genetics of antipsychotic treatment emergent weight gain in schizophrenia Pharmacogenomics 7 863-887
  • [2] Kennedy JL(2005)Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209-1223
  • [3] Lieberman JA(2006)Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 1079-1087
  • [4] Stroup TS(2005)Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation Psychiatry Res 133 273-276
  • [5] McEvoy JP(2005)Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs Psychiatr Genet 15 285-289
  • [6] Swartz MS(2003)Association of −2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain Zhonghua Yi Xue Za Zhi 83 2119-2123
  • [7] Rosenheck RA(2005)Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis Pharmacogenet Genomics 15 195-200
  • [8] Perkins DO(2007)Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia Psychopharmacol Bull 40 57-62
  • [9] Jones PB(2007)Association of the Int J Neuropsychopharmacol 10 697-704
  • [10] Barnes TR(2005) gene and antipsychotic induced weight gain: a meta-analysis Exp Brain Res 166 137-146
12345678910